Media Articles Related to Tykerb (Lapatinib)
pCR and Improved Survival in Breast Cancer?
Source: Medscape Hematology-Oncology Headlines [2014.09.11]
Dr. Lidia Schapira discusses an analysis of NeoALTTO, which indicates that achieving pCR after neoadjuvant therapy for HER2+ cancer is associated with improved outcomes -- for some more than others.
'Got It Right': Guidelines for HER2-Negative Breast Cancer
Source: Medscape Hematology-Oncology Headlines [2014.09.10]
Dr. Kathy Miller says the ASCO guidelines for advanced HER2-negative breast cancer 'got it right,' focusing on HT, sequential chemo agents, and decisions made jointly by doctors and patients.
New genetic target for a different kind of cancer drug should benefit lung and breast cancer patients
Source: Breast Cancer News From Medical News Today [2014.09.10]
Upstream of the proteins that cancer cells use to proliferate sits RBM4, a gene-splicing protein that UNC researcher Zefeng Wang, PhD, discovered is drastically reduced in human lung and breast...
97 percent of elderly patients aged above 80 years recover without major complications after breast cancer surgery
Source: Breast Cancer News From Medical News Today [2014.09.09]
A study conducted by National Cancer Centre Singapore (NCCS) has shown that age per se is not a contraindication to breast cancer surgery, and such surgeries may be safely performed for women aged 80...
Advance reported in treatment of triple-negative breast cancer
Source: Breast Cancer News From Medical News Today [2014.09.09]
William M. Sikov, a medical oncologist in the Breast Health Center and associate director for clinical research in the Program in Women's Oncology at Women & Infants Hospital of Rhode Island, served...
Published Studies Related to Tykerb (Lapatinib)
Target-specific, histology-independent, randomized discontinuation study of
lapatinib in patients with HER2-amplified solid tumors. 
focused on the drug target rather than on histology... CONCLUSIONS: Basing trial eligibility on the presence of a genetic target, versus
Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck. [2011.08.23]
BACKGROUND: Lapatinib is a dual inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER-2) tyrosine kinases. This study investigated the pharmacodynamic and clinical effects of lapatinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)... CONCLUSION: Short-term lapatinib monotherapy did not demonstrate apoptotic changes, but provided evidence of clinical activity in locally advanced SCCHN, and warrants further investigation in this disease.
Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial. [2011.08]
Dual epidermal growth factor receptor (EGFR) and HER2 targeting with the tyrosine kinase inhibitor lapatinib is approved for treating advanced HER2-positive breast cancer and can prevent estrogen receptor (ER)-negative mammary tumors in HER2 transgenic mouse models... In conclusion, short-term lapatinib decreased cell proliferation in DIN, DH, and invasive HER-2-positive (especially ER-negative) breast cancer, thus providing the rationale for further clinical development of lapatinib for breast cancer prevention in high-risk patients, including those with HER-2-positive DIN.
A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors. [2011.03.01]
BACKGROUND: Metastatic colorectal cancer (mCRC) is a leading cause of cancer-related mortality in the United States, and new treatment options are needed. This phase I study investigated a novel regimen combining 2 chemotherapy drugs with proven efficacy in mCRC (capecitabine and oxaliplatin) with a tyrosine kinase inhibitor (lapatinib). Lapatinib has already been approved by the US Food and Drug Administration for treatment of selected cases of breast cancer... CONCLUSION: Results of this study suggest the regimen of capecitabine, oxaliplatin, and lapatinib has some efficacy in types of advanced or metastatic solid malignancies with known responsiveness to fluoropyrimidines or oxaliplatin. Further research may help determine whether this regimen can improve on the response rates seen with current standard regimens for mCRC.
Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. [2010.08.01]
PURPOSE: Pazopanib and lapatinib are tyrosine kinase inhibitors that target vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit or epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/neu), respectively. In cervical cancer, EGFR and HER2/neu overexpression and high microvascular density correlate with survival... CONCLUSION: This study confirms the activity of antiangiogenesis agents in advanced and recurrent cervical cancer and demonstrates the benefit of pazopanib based on the prolonged PFS and favorable toxicity profile.
Clinical Trials Related to Tykerb (Lapatinib)
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer [Recruiting]
The double blind part of the study is being conducted to compare the efficacy and safety of
pazopanib in combination with lapatinib with that of lapatinib alone in subjects with
inflammatory breast cancer whose tumors overexpress the ErbB2 protein. There is also an
Open-label pazopanib arm to this study designed to test whether pazopanib given alone and
lapatinib given alone would be safe and effective to treat patients with inflammatory breast
Preoperative Chemotherapy With Paclitaxel, Gemcitabine, and Lapatinib (Tykerb´┐Ż) (PGT) [Recruiting]
Primary objectives :
1. To evaluate the recommended dose of the combination of paclitaxel, gemcitabine, and
lapatinib (Tykerb«) (PGT) as preoperative chemotherapy in patients with HER2 positive
operable breast cancer
Secondary objectives :
1. To evaluate the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of PGT
2. To determine the safety profile
3. To assess pCR in primary tumor and axillary LN
4. To evaluate clinical response rate, disease free survival (DFS), and overall survival
5. To assess breast conserving rate after preoperative PGT
Lapatinib and Cetuximab in Patients With Solid Tumors [Recruiting]
This trial is for patients with colon cancer, head and neck cancer and lung cancer that has
not responded to standard therapy.
Cetuximab targets a receptor on cancer cells called the Epidermal Growth Factor Receptor or
EGFR. It is thought that this receptor is turned "on" in some cancers, enabling cancer cells
to divide and grow. Blocking this receptor can turn this signal off. Cetuximab blocks this
receptor from the outside of cancer cells. It is thought that cancer cells can turn this
signal back on by the EGFR joining with a related receptor called ErbB2. Lapatinib blocks
both EGFR and ErbB2 from the inside of cancer cells. In laboratory experiments it has been
found that combining drugs that target both EGFR and ErbB2 might work better in turning this
signal back off. The purpose of this study is to determine the maximum dosages that patients
can tolerate when these two medicines are given at the same time.
In addition, in order to be on this trial, patients must agree to have a tumor biopsy before
starting treatment on this study and 21 days after starting treatment. These biopsies are a
required part of the study. Patients must also agree to have blood drawn for research
testing to see whether genetic differences between patients explain different reactions to
and side effects from, these medicines.
Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy [Recruiting]
Two thirds or more of breast cancers are dependent on estrogen for growth. We use a number
of estrogen-blocking medicines for treatment of metastatic breast cancer. The treatment
response to these agents is unpredictable, however, and approximately one-third of patients
with metastatic breast cancer with receptors for estrogen or progesterone have no benefit
from hormonal therapy. Nearly all patients with metastatic breast cancer will eventually
become resistant to hormonal therapy despite the fact that the hormone receptors are still
Some cells make a different class of growth factor receptor called the Epidermal Growth
Factor Receptor. There is a growing body of experimental evidence showing that breast
cancer cells that make Epidermal Growth Factor Receptors are more resistant to hormonal
therapy and have a poorer prognosis. Several investigators have found that the Epidermal
Growth Factor Receptor can activate the estrogen receptor, even in the presence of
estrogen-blocking drugs. Growth of these cells can be slowed by blockade of both Epidermal
Growth Factor Receptor signaling and estrogen-receptor signaling. Lapatinib is a small
molecule which can inhibit two different forms of the Epidermal Growth Factor Receptor. It
has been studied in people with a number of different cancers, including breast cancer, and
a safe dose and its common side effects have been defined.
Our hypothesis is that the Epidermal Growth Factor Receptor is the dominant receptor pathway
used by breast cancers in our patients with hormone-resistant tumors. Drugs like lapatinib
which block several forms of the Epidermal Growth Factor Receptor would best be able to
reverse resistance to hormonal agents.
Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer [Recruiting]
This is a phase I/II study to determine the safety and gain insight into the immune response
of the immunologic agent dHER2+AS15 ASCI when administered in combination with lapatinib.
This study is for patients with metastatic breast cancer (invasive breast cancer with stage
IV disease) that overexpresses HER2 and is resistant to trastuzumab (Herceptin).
The dHER2 + AS15 candidate Antigen-Specific Cancer Immunotherapeutic (ASCI) contains a
recombinant protein termed dHER2, which is a truncated version of the HER2 protein. HER2 is
a protein that is commonly overexpressed in breast cancer. This protein is combined with the
immunological adjuvant AS15 Adjuvant System from GSK (GlaxoSmithKline), which is a liposomal
formulation containing three immunostimulatory components.
Lapatinib is FDA approved for use in combination with capecitabine for the treatment of
subjects with advanced or metastatic breast cancer whose tumors overexpress HER2.
Reports of Suspected Tykerb (Lapatinib) Side Effects
Palmar-Plantar Erythrodysaesthesia Syndrome (84),
Decreased Appetite (46),
Disease Progression (44), more >>